Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
ConditionRhumatoid Arthisis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorTanta University
About this trial
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
Eligibility criteria
Qualifiers
Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) >2.6.
Patients receiving the conventional DMARDs
Disqualifiers
Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.
Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.
Patients receiving oral prednisolone greater than 15mg/day.
Patients with hypersensitivity to study medications.
Trial design
Treatments tested in this trial
- Nicorandil 5 MG Oral Tablet
Treatment groups
46 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov